Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Interest Expense

Cost of servicing the company's debt during the period.

Solid Biosciences Inc.NASDAQ: SLDB

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $68K a year earlier. Trailing-twelve-month interest expense was $60K.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $15K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$60K-80.8% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Interest Expense vs competitors

How SLDB compares with its peers on the latest reported figures

  • SLDB's LTM Mar 2026 interest expense of $60K is the 6th highest of the 10 companies compared; the peer median is $3.05M.
  • Its year-over-year change of -80.8% is the lowest of 6, against a peer median of +25.9%.
SLDB Competitors Peer median
Interest Expense for SLDB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$185.29M +25.9%+18.8%18.4%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$42.07M +124.6%-43.3%1.9%
DYNDyne Therapeutics, Inc.LTM Jun 2026$14.9M +15745.7%+28.5%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$12M -8.1%+35.1%15.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.05M ———
SLDBSolid Biosciences Inc.LTM Mar 2026$60K -80.8%——
NGNENeurogene Inc.LTM Mar 2026$3K -72.7%+35.7%—
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$0 ———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
PEPGPepGen Inc.LTM Mar 2026$0 ———
Peer median (excluding SLDB) $3.05M+25.9%+28.5%8.5%

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.62M8.09M000
Cost of Revenue002.58M2.46M1.64M
Gross Profit13.62M8.09M(2.58M)(2.46M)(1.64M)
Gross Margin100.0%100.0%———
Research & Development58.74M78.42M76.56M96.43M140.33M
Selling, General & Admin27.14M28.95M27.75M33.3M38.88M
Operating Expenses85.87M114.55M101.73M127.27M177.57M
Depreciation & Amortization2.96M2.41M2.58M2.46M1.64M
EBITDA(69.22M)(96.87M)(93.43M)(121.9M)(172.69M)
EBITDA Margin-508.3%-1196.8%———
Operating Income(72.25M)(106.45M)(104.32M)(129.73M)(179.21M)
Operating Margin-530.5%-1315.2%———
Interest Income64K2.62M7.14M9.47M9.9M
Interest Expense000340K0
Other Income / Expenses66K20.47M8.3M5.03M4.88M
Income Before Tax(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Pre-Tax Margin-530.0%-1062.3%———
Income Tax Expense00000
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Net Margin-530.0%-1062.3%———
EPS (Basic)(10.14)(10.10)(4.83)(3.06)(1.99)
EPS (Diluted)(10.14)(10.10)(4.83)(3.06)(1.99)
Weighted Avg Shares7.12M8.51M19.88M40.82M87.5M
Weighted Avg Shares (Diluted)7.12M8.51M19.88M40.82M87.5M

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.